Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Results of the study will likely be released one week after the blind is removed".
Exactly George, Leo is awaiting results as are the rest of us.
We have great anecdotal evidence from multiple patients as well as caregivers saying Anavex 273 has improved daily lives and activities to a highly functional level. All patients in the group requested to remain on drug even past 52 weeks. Trial was then expanded to 104 weeks. That evidence alone to me is worth the investment. As we know Shorts always post negative articles against Good companies.
PR From May 11 (last week) "Phase 2 clinical trial of Prurisol for the treatment of mild-to-moderate chronic plaque psoriasis is expected to be "unblinded" next week. Once the blind is removed, data from each of the four arms of the trial (one placebo arm, three oral dosing regimens of Prurisol) will be reviewed and analyzed to evaluate the safety and efficacy of Prurisol. Cellceutix expects to release top-line data from the study approximately one week after the blind is removed".
#poundsand
AAIC abstract criteria:
-Late-breaking research/newness of information.
-Potential impact on the research community.
-Quality of scientific research.
-Relevance to Alzheimer's disease and related disorders.
-Topics of interest include basic and translational science, diagnosis and prognosis, therapeutics, and public health and psychosocial issues.
https://alz.confex.com/alz/2016/dt/cfp.cgi
AAIC makes good sense. Prof Macfarlane reported further trial data mid-year. Dr Missling presented previous data at AAIC. This years AAIC Abstract submission deadline was May 2.
Looking for very positive data like the following in 2-3 weeks..
"Prurisol given at 10 mg/kg twice/day was shown to be more effective than methotrexate in reducing psoriatic skin lesions in a human xenograft model. In addition, Prurisol can be given orally and is well-tolerated".
See more at: http://cellceutix.com/prurisol/#sthash.A7EHNjSW.dpuf
Prurisol clinical trial updated to completed May2. Could get results anytime now.
https://clinicaltrials.gov/ct2/show/NCT02494479?term=ctix&rank=3
The Russell does a rebalance sometime in June. Look forward to AVXL being added then.
No where in the FUD articles do they tell readers that many trial patients have been on A-273 for a year or longer. That is where the rubber meets the road.
Fool is at it again. Again downplaying incredible cognitive improvement as placebo effect.
http://www.fool.com/investing/general/2016/04/26/could-a-pill-to-cure-alzheimers-disease-become-ava.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2
This anecdotal news from patients is huge for those holding. Most retail will have sold for a huge profit long before FDA approval.
Thanks for the response. Yes I agree news is imminent.
Do to shorts capitalizing on fretting retail selling we are again seeing some chinking in the Armour.
At this early stage Anavex stock progression is highly driven by results.
Looks like Fool is trying another some what negative run against Anavex.
http://www.fool.com/investing/general/2016/04/08/does-3-71-make-anavex-life-sciences-a-buy.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2
Exactly. These hit piece analysts don't spread fear on losers. This should rebound quickly.
You can't set in stone time lines on fragile elderly patients especially as time passes may need treatment for other health abnormalities. Dr. Missling said he will release PK/PD results when they are completed.
March 12 listed on the events calender..
http://www.anavex.com/?events=14th-international-athens-springfield-symposium-on-advances-in-alzheimer-therapy
I would think if the results were not good testers and patients would know so why go on with it.
"The subjects will now be followed for an additional 28 days without taking additional study medication". Reading between the lines here but why would they go ahead with the 28 day off period if the drug was not working.
Pfizer recently discontinued phase 2 testing of PF-05212377, a 5-HT6 receptor antagonist targeting amyloid plaques being developed for Alzheimer’s Disease. It has been reported that Axovant’s lead drug RVT-101 works by similar MOA.
"Now, this new p21 data only reinforces our high expectations for and confidence in Kevetrin, specifically, its potential to treat patients across a broad spectrum of cancer types and even those in late stages with refractory tumors. It is exciting to see our early clinical work in the lab translating to the bedside."
Treat patients across a broad spectrum of cancer types. Very positive statement.
On November 18 Anavex announced moving forward with a P2/3 double blind study based on formal interaction with the FDA. Most likely meeting would have occurred in October and after 10 months of first patient dosing. The positive FDA outcome in my opinion was also based on positive evidence seen in late dosing. Missling must have a plan and good reason to hold dosing news past the 52 week PARTB but clearly based on positive FDA outcome I would say patients past 52 weeks are still being dosed.
Once share price recovers he will be gone. Leo's resurrection of the company or the great pipeline is evidently being received as noise. Next 90 days could be very exciting. Thanks for your level headed posts.
Hey you never know...THC therapy, Missling has long hair maybe a collaboration in the works.hehe
Yes thanks I see Zynerba is ahead of Anavex. I missed that.
I see Zynerba Pharmaceuticals listed with Anavex. Is there a collaboration in the works?
http://www.epilepsy.com/search/site/anavex
This is a early In Vitro study. And yes it is more good news to those that follow the trials.
This is a early In Vitro study. And yes it is more good news to those that follow the trials.
Conference Abstract: P088: Sigma-1 Receptor Agonists Inhibit Oligodendrocyte Cytotoxicity Induced by Molecules Involved in Cell Damage in Multiple Sclerosis.
https://actrims.confex.com/actrims/2016/meetingapp.cgi/Paper/1218
ANAVEX2-73 reduced OL cell death induced by all 4 molecules by over 50%.
I look at it like this Frrol. In mid-November Anavex announced under FDA Guidance they were moving ahead with a larger Phase2/3 trial. Since the announcement was in November the first patients would have been 11months into dosing so with them proceeding shows me they were still seeing drug efficacy and not a relapse in the long term.
Starting at 1:07 in the message Dr Missling said Last month was the most relevant information that we saw with Anavex 273. Very strong dose response curve in two independent cognitive markers.
Just last month so possibly some 12 week tidbits. Great news anyway.
Mine too. The FDA now has a history with Kevetrin and likes what they see.
Last bullet on slide 31 says.."Additional data, including updates on Part B to be presented at upcoming scientific meetings" He also says on that slide that 52 week Part B extension trial is ongoing.
You make a good case Frrol. However next data release promised this quarter. Missling said "scientific meeting". He wouldn't hold trial impacting bad news for a scientific meeting as a release to his peers would he.
Frrol you make very valid points but even as late as January 11 Missling said "we look forward to advancing ANAVEX 2-73 into a larger Phase 2/3 study for Alzheimer’s". I could be all wrong here but one would have to ascertain from that statement that first patients would keep dosing as they dove tail the trial into Phase 2/3. Hopefully this will all be cleared up at the next "scientific meeting". It would have been nice if Missling would have thrown shareholder a bone though.
Agree Dane. I think today was juice for the big pharma crowd. Just a guess anyway.
Missling did say additional data, including updates on PART B to be presented at upcoming scientific meetings. He should at least PR the next scientific venue soon.
I would just say this. If full 12 week data was looking negative as eluded to how could he be going to an investors conference trying to rope in new money especially with SEC investigating price manipulation.
For now we have a positive from slide 9 to hang our hats on. Interim Data Anavex 2-73 increases ADCS-ADL by +3.21 points from baseline at 12 weeks.
Alzheimer’s Disease Co-operative Study - Activities of Daily Living Inventory (ADCS-ADL)